NeuroPaceNPCE +2.41%68 14-Day RSI is 51.63 as of Jul. 04, 2026. GuruFocus rates NPCE with a GF Score™ of 68/100 and a GF Value™ of $11.41 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 870 Medical Devices & Instruments companies, NeuroPace ranks worse than 64.94% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-04), NeuroPace's 14-Day RSI is 51.63.
The industry rank for NeuroPace's 14-Day RSI or its related term are showing as below:
NPCE's 14-Day RSI is ranked worse than 64.94% of 870
companies
in the Medical Devices & Instruments industry
Industry Median: 47.555
vs NPCE: 51.63
NeuroPace (NAS:NPCE) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
NeuroPace 14-Day RSI Related Terms
NPCE vs CLPT, CTKB, CERS: 14-Day RSI Comparison
For the Medical Devices subindustry, NeuroPace's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuroPace 14-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NeuroPace's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where NeuroPace's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuroPace (NPCE) has a 14-Day RSI of 51.63 as of Jul. 04, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on NeuroPace and its competitors. According to the industry distribution chart, NeuroPace ranks #565 out of 870 companies in the Medical Devices & Instruments industry, placing it in the top 64.9%.
Is NeuroPace's 14-Day RSI too high?
NeuroPace's current 14-Day RSI is 51.63. The Medical Devices & Instruments industry median 14-Day RSI is 47.56. NeuroPace's value of 51.63 is 8.6% above this industry median. Based on the distribution chart, NeuroPace ranks #565 out of 870 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, NeuroPace has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NeuroPace's 14-Day RSI compare to CLPT and CTKB?
According to the Medical Devices & Instruments industry distribution chart, NeuroPace ranks #565 out of 870 companies for 14-Day RSI. This places NeuroPace in the lower half of its industry. The industry median 14-Day RSI is 47.56. NeuroPace's value of 51.63 is 8.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Devices & Instruments company?
The median 14-Day RSI among Medical Devices & Instruments companies is 47.56, based on 870 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeuroPace's current 14-Day RSI of 51.63 is 8.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on NeuroPace and its competitors. For the Medical Devices & Instruments industry, the median 14-Day RSI is 47.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuroPace's current 14-Day RSI is 51.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroPace stock overvalued right now?
Based on GuruFocus' analysis, NeuroPace (NPCE) is currently considered Significantly Overvalued. The stock's GF Value™ is $11.41, compared to a current price of $16.17 — trading 41.7% above its estimated fair value. The current 14-Day RSI is 51.63 and 8.6% above the Medical Devices & Instruments industry median of 47.56. NeuroPace's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For NeuroPace (NPCE), the current 14-Day RSI is 51.63 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeuroPace (NPCE) Overvalued in 2026?
Based on GuruFocus' analysis, NeuroPace stock appears to be overvalued.
The current stock price of $16.17 is trading 41.7% above its estimated GF Value™ of $11.41.
GuruFocus considers NeuroPace to be Significantly Overvalued.
Key valuation signals for NPCE:
14-Day RSI: 51.63
GF Value™: $11.41 vs. price of $16.17 (41.7% above fair value)
Industry Position: 8.6% above the Medical Devices & Instruments median (#565 of 870)
No single metric tells the full story. See the NPCE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
68GF Score
Get the complete analysis for NPCE
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NPCE has been successfully added to your 